These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 22563515)

  • 1. Development of a humanized antibody with high therapeutic potential against dengue virus type 2.
    Li PC; Liao MY; Cheng PC; Liang JJ; Liu IJ; Chiu CY; Lin YL; Chang GJ; Wu HC
    PLoS Negl Trop Dis; 2012; 6(5):e1636. PubMed ID: 22563515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine.
    Tsai WY; Chen HL; Tsai JJ; Dejnirattisai W; Jumnainsong A; Mongkolsapaya J; Screaton G; Crowe JE; Wang WK
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30185598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2.
    Sukupolvi-Petty S; Austin SK; Engle M; Brien JD; Dowd KA; Williams KL; Johnson S; Rico-Hesse R; Harris E; Pierson TC; Fremont DH; Diamond MS
    J Virol; 2010 Sep; 84(18):9227-39. PubMed ID: 20592088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotype-specific neutralization and protection by antibodies against dengue virus type 3.
    Brien JD; Austin SK; Sukupolvi-Petty S; O'Brien KM; Johnson S; Fremont DH; Diamond MS
    J Virol; 2010 Oct; 84(20):10630-43. PubMed ID: 20702644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes.
    Sukupolvi-Petty S; Austin SK; Purtha WE; Oliphant T; Nybakken GE; Schlesinger JJ; Roehrig JT; Gromowski GD; Barrett AD; Fremont DH; Diamond MS
    J Virol; 2007 Dec; 81(23):12816-26. PubMed ID: 17881453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection.
    Sukupolvi-Petty S; Brien JD; Austin SK; Shrestha B; Swayne S; Kahle K; Doranz BJ; Johnson S; Pierson TC; Fremont DH; Diamond MS
    J Virol; 2013 Aug; 87(16):8826-42. PubMed ID: 23785205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of Monoclonal Antibodies against Dengue Virus Type 4 and Identification of Enhancing Epitopes on Envelope Protein.
    Tang CT; Liao MY; Chiu CY; Shen WF; Chiu CY; Cheng PC; Chang GJ; Wu HC
    PLoS One; 2015; 10(8):e0136328. PubMed ID: 26309127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization.
    Lin HH; Yang SP; Tsai MJ; Lin GC; Wu HC; Wu SC
    Theranostics; 2019; 9(16):4811-4826. PubMed ID: 31367259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.
    Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K
    Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein.
    Budigi Y; Ong EZ; Robinson LN; Ong LC; Rowley KJ; Winnett A; Tan HC; Hobbie S; Shriver Z; Babcock GJ; Alonso S; Ooi EE
    PLoS Negl Trop Dis; 2018 Feb; 12(2):e0006209. PubMed ID: 29425203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epitope determinants of a chimpanzee dengue virus type 4 (DENV-4)-neutralizing antibody and protection against DENV-4 challenge in mice and rhesus monkeys by passively transferred humanized antibody.
    Lai CJ; Goncalvez AP; Men R; Wernly C; Donau O; Engle RE; Purcell RH
    J Virol; 2007 Dec; 81(23):12766-74. PubMed ID: 17881450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
    Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
    BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity.
    Beltramello M; Williams KL; Simmons CP; Macagno A; Simonelli L; Quyen NT; Sukupolvi-Petty S; Navarro-Sanchez E; Young PR; de Silva AM; Rey FA; Varani L; Whitehead SS; Diamond MS; Harris E; Lanzavecchia A; Sallusto F
    Cell Host Microbe; 2010 Sep; 8(3):271-83. PubMed ID: 20833378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones.
    Smith SA; de Alwis AR; Kose N; Jadi RS; de Silva AM; Crowe JE
    J Virol; 2014 Nov; 88(21):12233-41. PubMed ID: 25100837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected].
    Williams KL; Sukupolvi-Petty S; Beltramello M; Johnson S; Sallusto F; Lanzavecchia A; Diamond MS; Harris E
    PLoS Pathog; 2013 Feb; 9(2):e1003157. PubMed ID: 23459315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection.
    Tsai WY; Lai CY; Wu YC; Lin HE; Edwards C; Jumnainsong A; Kliks S; Halstead S; Mongkolsapaya J; Screaton GR; Wang WK
    J Virol; 2013 Dec; 87(23):12562-75. PubMed ID: 24027331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1.
    Messer WB; Yount BL; Royal SR; de Alwis R; Widman DG; Smith SA; Crowe JE; Pfaff JM; Kahle KM; Doranz BJ; Ibarra KD; Harris E; de Silva AM; Baric RS
    J Virol; 2016 May; 90(10):5090-5097. PubMed ID: 26962223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
    Nivarthi UK; Kose N; Sapparapu G; Widman D; Gallichotte E; Pfaff JM; Doranz BJ; Weiskopf D; Sette A; Durbin AP; Whitehead SS; Baric R; Crowe JE; de Silva AM
    J Virol; 2017 Mar; 91(5):. PubMed ID: 28031369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Effects of Monoclonal Antibody against Dengue Virus NS1 in a STAT1 Knockout Mouse Model of Dengue Infection.
    Wan SW; Chen PW; Chen CY; Lai YC; Chu YT; Hung CY; Lee H; Wu HF; Chuang YC; Lin J; Chang CP; Wang S; Liu CC; Ho TS; Lin CF; Lee CK; Wu-Hsieh BA; Anderson R; Yeh TM; Lin YS
    J Immunol; 2017 Oct; 199(8):2834-2844. PubMed ID: 28904127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine.
    Galula JU; Shen WF; Chuang ST; Chang GJ; Chao DY
    J Virol; 2014 Sep; 88(18):10813-30. PubMed ID: 25008922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.